the prognostic value of flt3-itd residual disease in aml
Published 1 year ago • 260 plays • Length 1:49Download video MP4
Download video MP3
Similar videos
-
3:03
prognostic impact of flt3-itd in older patients with aml
-
3:21
the prognostic impact of flt3-itd and flt3-tkd in npm1-mutated aml
-
1:39
quantum-first: flt3-itd-specific mrd clearance is associated with improved os in newly diagnosed aml
-
1:12
the value of flt3 inhibitors in aml and focus for future trial designs
-
1:59
tangible benefit for flt3-itd r/r aml on quizartinib
-
2:08
comparing midostaurin to next-generation flt3 inhibitors in the frontline treatment of flt3-itd aml
-
1:40
second-generation flt3 inhibitors in the treatment of flt3-itd aml
-
1:06
investigating the molecular and clinical features of flt3-jmd mutations in aml
-
0:58
flt3 mutation clearance rate in patients with newly diagnosed aml
-
2:55
the importance of flt3 inhibitors in aml and factors to consider when choosing between these agents
-
2:29
flt3 inhibitors as maintenance therapy in aml
-
0:49
treatment avenues for patients with r/r flt3-mutated aml: optimizing flt3 inhibitors
-
1:32
novel treatment combinations for flt3-mutated aml
-
1:55
assessing flt3-itd-specific mrd clearance using a pcr-ngs assay in the quantum-first trial
-
1:33
prognostic impact of wt1 mutations in newly diagnosed and r/r aml
-
3:03
quantum-first: flt3-itd-specific mrd to assess benefits of quizartinib in flt3-itd aml
-
2:35
quizartinib for frontline flt3-itd aml: updated results from the quantum-first trial
-
1:57
insights into the treatment of patients with flt3-mutated aml & the role of maintenance therapy
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo